PEPGEN
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and they are advancing novel conjugate therapeutics to the clinic.
PEPGEN
Industry:
Biotechnology Clinical Trials Medical
Founded:
2018-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.pepgen.com
Total Employee:
11+
Status:
Active
Contact:
+44 1865 618 820
Total Funding:
159.58 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Sitelinks Search Box Euro Organization Schema IPv6
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
HebeCell
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
Home Biosciences
Home Biosciences is a European venture builder dedicated to biotech.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Onego Bio
Onego Bio is a smart protein is a piece of cake.
Upacjenta
Upacjenta is to popularize preventive laboratory tests among Polish women and Poles.
Venn Life Sciences
Contract research providing clinical trial services from pre-clinical to Phase III
Current Advisors List
Board_observer
2019-01-01
Current Employees Featured
Jaya Goyal Executive Vice President, Research & Preclinical Development @ Pepgen
Executive Vice President, Research & Preclinical Development
2021-10-01
James McArthur Chief Executive Officer @ Pepgen
Chief Executive Officer
2021-01-01
Matthew Wood Co-Founder @ Pepgen
Co-Founder
Caroline Godfrey SVP of Discovery @ Pepgen
SVP of Discovery
Michael Gait Co-Founder @ Pepgen
Co-Founder
Founder
Stock Details
Investors List
Laurion Capital Management
Laurion Capital Management investment in Venture Round - Pepgen
CureDuchenne Ventures
CureDuchenne Ventures investment in Venture Round - Pepgen
Viking Global Investors
Viking Global Investors investment in Venture Round - Pepgen
Gray’s Creek Capital Partners
Gray’s Creek Capital Partners investment in Venture Round - Pepgen
Adage Capital Management
Adage Capital Management investment in Venture Round - Pepgen
Samsara BioCapital
Samsara BioCapital investment in Venture Round - Pepgen
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - Pepgen
RA Capital Management
RA Capital Management investment in Venture Round - Pepgen
Tudor Investments
Tudor Investments investment in Venture Round - Pepgen
Deerfield
Deerfield investment in Venture Round - Pepgen
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-08 | PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development |
Official Site Inspections
http://www.pepgen.com Semrush global rank: 4.28 M Semrush visits lastest month: 2.69 K
- Host name: 2.124.145.34.bc.googleusercontent.com
- IP address: 34.145.124.2
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Pepgen.com lookup results from whois.namebright.com server:
- Domain created: 9th-Feb-2015
- Domain updated: 10th-Jan-2025
- Domain expires: 9th-Feb-2030 4 Years, 247 Days left
- Website age: 10 Years, 118 Days
- Registrar Domain ID: 1901714129_DOMAIN_COM-VRSN
- Registrar Url: http://www.NameBright.com
- Registrar WHOIS Server: whois.namebright.com
- Registrar Abuse Contact Email: support@namebright.com
- Registrar Abuse Contact Phone: 17204960020
- Name server:
- NS1.NAMEBRIGHTDNS.COM
- NS2.NAMEBRIGHTDNS.COM
More informations about "Pepgen"
About – PepGen
Prior to PepGen, Kyle held roles of increasing responsibility with the finance group at Orchard Therapeutics, where he was a key partner in the Company’s IPO and multiple successful …See details»
Pepgen - Crunchbase Company Profile & Funding
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their …See details»
Science – PepGen
PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform Our EDO platform, founded on over a decade of research and development, is designed to overcome the key challenges facing previous attempts to target neuromuscular diseases …See details»
Investor FAQs - PepGen
The Investor Relations website contains information about PepGen's business for stockholders, potential investors, and financial analysts.See details»
Pepgen - 2025 Company Profile & Funding - Tracxn
May 1, 2025 Pepgen is a public company based in Oxford (United Kingdom), founded in 2018 by Michael Gait and Caroline Godfrey. It operates as a Provider of various therapeutics. Pepgen …See details»
PepGen - The Org
Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the …See details»
Pepgen Corporation - VentureRadar
"PepGen is revolutionizing the treatment of neuromuscular diseases through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company focuses on developing a …See details»
PepGen Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 PepGen has 3 employees at their 1 location. See insights on PepGen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
PepGen Company Profile | Management and Employees List
Find contact information for PepGen. Learn about their Research & Development, Business Services market share, competitors, and PepGen's email format.See details»
PepGen Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore PepGen Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 87 news, and 11 literature, Disease Domain:Nervous System ...See details»
20 Things You Didn't Know about PepGen - Money Inc
May 27, 2022 12. PepGen went pubic recently PepGen went public on May 5, 2022. The company moved from a private venture capital-backed organization to one that offers shares …See details»
Pepgen - Crunchbase Company Profile & Funding
Pepgen is a privately-held biopharmaceutical company that develops novel products for the treatment of autoimmune and viral disorders.See details»
PepGen Reports First Quarter 2025 Financial Results and Recent ...
2 hours ago PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular …See details»
PepGen Announces Appointment of Two New Directors to its …
Mar 31, 2025 BOSTON -- (BUSINESS WIRE)--Mar. 31, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide …See details»
Contact – PepGen
General Inquiries info@pepgen.com Community Inquiries community@pepgen.com Clinical Trials clinicaltrials@pepgen.com Careers Inquiries careers@pepgen.com Investor Inquiries …See details»
PepGen - Work in biotech
PepGen Therapeutics is creating the next generation of oligonucleotide therapies to transform treatments of neuromuscular diseases. Oligonucleotides delivered into cells can modulate …See details»
PepGen Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
A PepGen drug in development for myotonic dystrophy type 1 (DM1) has encouraging early human data that suggest it could be a better treatment than other medicines in clinical testing …See details»
PepGen - Oxford Science Enterprises
PepGen is a clinical stage biotech developing next-generation oligonucleotide therapies for patients with Duchenne's Muscular Dystrophy and other rare diseases.See details»
Pipeline – PepGen
PepGen is advancing a pipeline of disease-modifying, peptide-conjugated oligonucleotide candidates to treat neuromuscular and neurological diseases, beginning with Duchenne …See details»
PepGen Reports First Quarter 2025 Financial Results and Recent ...
1 hour ago PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe …See details»